UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

BMJ (Online), 2012-07, Vol.345 (jul19 1), p.e4565-e4565

2012

Volltextzugriff (PDF)

Endoscopic ultrasound of the colon for the differentiation of Crohn's disease and ulcerative colitis in comparison with healthy controls

Alimentary pharmacology & therapeutics, 2014-04, Vol.39 (8), p.823-833

2014

Volltextzugriff (PDF)

Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis

Gut, 2006-06, Vol.55 (6), p.833-841

2006

Volltextzugriff (PDF)

Anti-Integrin-Therapie der chronischentzündlichen Darmerkrankungen

Verdauungskrankheiten, 2024-03, Vol.42 (3), p.64-70

Kuehbacher, T.

2024

Volltextzugriff (PDF)

OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S001-S002

2021

Volltextzugriff (PDF)

Influence of CYP3A4, CYP3A5, and ABCB1 Genotype and Expression on Budesonide Pharmacokinetics: A Possible Role of Intestinal CYP3A4 Expression

Clinical pharmacology and therapeutics, 2008-07, Vol.84 (1), p.43-46

2008

Volltextzugriff (PDF)

Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (5), p.581-587

2018

Volltextzugriff (PDF)

Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease

Journal of medical microbiology, 2008-12, Vol.57 (12), p.1569-1576

2008

Volltextzugriff (PDF)

P789 Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1471-i1473

2024

Volltextzugriff (PDF)

P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1330-i1332

2024

Volltextzugriff (PDF)

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

The New England journal of medicine, 2019-09, Vol.381 (13), p.1215-1226

2019

Volltextzugriff (PDF)

Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study

Gut, 2020-09, Vol.69 (9), p.1629-1636

2020

Volltextzugriff (PDF)

Vedolizumab for the Treatment of Chronic Pouchitis

The New England journal of medicine, 2023-03, Vol.388 (13), p.1191-1200

2023

Volltextzugriff (PDF)

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS): AWMF Registry 021/009

Zeitschrift für Gastroenterologie, 2019-02, Vol.57 (2), p.162-241

2019

Volltextzugriff (PDF)

P588 Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S380-S380

2017

Volltextzugriff (PDF)

P544 Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease course

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S357-S357

2017

Volltextzugriff (PDF)

Improvement of arthritis/arthralgia after treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease

Gastroenterology (New York, N.Y. 1943), 2001-04, Vol.120 (5), p.A621-A621

2001

Volltextzugriff (PDF)

Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers

Zeitschrift fur Gastroenterologie, 2020-07, Vol.58 (7), p.672

2020

Volltextzugriff (PDF)

Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease

The American journal of gastroenterology, 2002-10, Vol.97 (10), p.2688-2690

2002

Volltextzugriff (PDF)

DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S70-S71

2017

Volltextzugriff (PDF)

OP023 Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S13-S14

2017

Volltextzugriff (PDF)

A comparison of oligonucleotide and cDNA-based microarray systems

Physiological genomics, 2004-02, Vol.16 (3), p.361-370

2004

Volltextzugriff (PDF)

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

The lancet. Gastroenterology & hepatology, 2024-02, Vol.9 (2), p.133-146

2024

Volltextzugriff (PDF)

Pouchitis : pathophysiology and treatment

International journal of colorectal disease, 1998-12, Vol.13 (5-6), p.196-207

1998

Volltextzugriff (PDF)

Pouchitis and the risk of cancer?

International journal of colorectal disease, 2001-04, Vol.16 (2), p.131-131

Kuehbacher, T

2001

Volltextzugriff (PDF)

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(135)
Mit Volltextzugriff
(117)

Publikationsform

Sprache

Englisch
(129)
Deutsch
(17)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

Endoscopic ultrasound of the colon for the differentiation of Crohn's disease and ulcerative colitis in comparison with healthy controls

Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis

Anti-Integrin-Therapie der chronischentzündlichen Darmerkrankungen

OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study

Influence of CYP3A4, CYP3A5, and ABCB1 Genotype and Expression on Budesonide Pharmacokinetics: A Possible Role of Intestinal CYP3A4 Expression

Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis

Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease

P789 Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis

P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study

Vedolizumab for the Treatment of Chronic Pouchitis

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS): AWMF Registry 021/009

P588 Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54

P544 Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease course

Improvement of arthritis/arthralgia after treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease

Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers

Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease

DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease

OP023 Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study

A comparison of oligonucleotide and cDNA-based microarray systems

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Pouchitis : pathophysiology and treatment

Pouchitis and the risk of cancer?

Suchergebnisse filtern